CD274 and intrahepatic cholangiocarcinoma: To our knowledge, this represents the first phase II trial investigating this triple-modality approach (HAIC-GC and sequential capecitabine/PD-L1 inhibition) as adjuvant therapy for resected high-risk ICC.